Next Article in Journal
Cancer Cachexia: Muscle Physiology and Exercise Training
Next Article in Special Issue
Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
Previous Article in Journal
A Comment on Qi et al.: An Estimation of Radiobiological Parameters for Head-and-Neck and the Clinical Implications. Cancers, 2012, 4, 566-580
Previous Article in Special Issue
Immune Response to Sipuleucel-T in Prostate Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2012, 4(4), 1229-1246; doi:10.3390/cancers4041229

Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response

1
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
2
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
Received: 8 October 2012 / Revised: 9 November 2012 / Accepted: 14 November 2012 / Published: 22 November 2012
(This article belongs to the Special Issue Immune Responses to Human Prostate Cancer)
View Full-Text   |   Download PDF [156 KB, uploaded 22 November 2012]

Abstract

Despite recent advances in cancer immunotherapy, no prospectively validated intermediate biomarkers exist to predict response. These biomarkers are highly desirable given modern immunotherapy’s paradoxical pattern of clinical benefit; that is, improvement in overall survival without short-term change in progression. Immunotherapy clinical trials have evaluated biomarkers that may correlate with clinical outcomes. Many of them are performed on peripheral blood to evaluate the systemic response, such as tumor-targeted humoral and cellular immunity, and cytokine responses. Accumulating evidence suggests that immune infiltrates in tumors may suggest evidence for the therapy’s mechanism of action, and have greater potential for providing prognostic and predictive information. In addition, a non-immunologic biomarker, such as tumor growth kinetics, may explain this paradoxical pattern of clinical benefit, and predict survival in patients treated with an immunotherapy. Prospective assessment and validation of these and other intermediate markers would be required to better understand their potential clinical role. View Full-Text
Keywords: surrogate marker; immune assay; tumor-infiltrating lymphocytes; tumor growth rate surrogate marker; immune assay; tumor-infiltrating lymphocytes; tumor growth rate
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kim, J.W.; Bilusic, M.; Heery, C.J.; Madan, R.A. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers 2012, 4, 1229-1246.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top